Decreased TXNRD1 is associated with resistance to tagraxofusp in blastic plasmacytoid dendritic cell neoplasms, as seen in phase II
Open Access
- 6 July 2026
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 40 (9) , 1951-1960
Abstract
Tagraxofusp is a CD123-targeted therapy comprised of a recombinant human interleukin-3 (IL-3) fused to a truncated diphtheria toxin payload. It is the first approved treatment specifically for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). To identify biomarkers of response, bone marrow samples from 12 BPDCN patients who were treated with tagraxofusp in the pivotal phase II trial (NCT02113982) were profiled longitudinally using a gene panel and single-cell RNA sequencing. Residual tumor cells following tagraxofusp expressed lower levels of TXNRD1 that would reduce the efficacy of tagraxofusp. In support of this, enzymatic inhibition of TXNRD1 resulted in higher viability of CAL-1 BPDCN cells following tagraxofusp. Responders had either wild-type or missense TET2 mutations, while transient and non-responders had at least one truncating TET2 mutation. Examples of these mutations within the catalytic domain of TET2 were constructed and transduced into cells. Missense and truncating mutants displayed reduced sensitivities to hypomethylating agents and prolonged S-phase stasis. These results suggest that the levels of TXNRD1 interact with intrinsic TET2 truncating mutations within the bone marrow to modulate patient response to tagraxofusp.Keywords
Funding Information
- Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research
- The University of Texas MD Anderson Cancer Center Internal Research Grant
- U.S. Department of War (CA190171)
- U.S. Department of War (CA190171)
- Cancer Prevention and Research Institute of Texas (R120501)
- Sheikh Mohamed Bin Zayed Al Nahyan Distinguished University Chair in Cancer Research
This publication has 58 references indexed in Scilit:
- Blastic plasmacytoid dendritic cell neoplasm: diagnostic criteria and therapeutical approachesBritish Journal of Haematology, 2016
- Thioredoxin reductase inhibitor auranofin prevents membrane transport of diphtheria toxin into the cytosol and protects human cells from intoxicationToxicon, 2016
- Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agentsNature Communications, 2016
- Protein Tyrosine Phosphatase PTPRS Is an Inhibitory Receptor on Human and Murine Plasmacytoid Dendritic CellsImmunity, 2015
- Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasmLeukemia, 2013
- Cytotoxic and non‐cytotoxic roles of the CTL/NK protease granzyme BImmunological Reviews, 2010
- LILRA2 Activation Inhibits Dendritic Cell Differentiation and Antigen Presentation to T CellsThe Journal of Immunology, 2007
- The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complexJournal of Cell Biology, 2003
- Developmental Regulation of Invariant Chain Proteolysis Controls MHC Class II Trafficking in Mouse Dendritic CellsCell, 1998
- Cell penetration of diphtheria toxin. Reduction of the interchain disulfide bridge is the rate-limiting step of translocation in the cytosol.Journal of Biological Chemistry, 1993